Evidence map›Paper›PMID 29018027›Full record

Trial reportJournal of the American Heart Association2017

Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial.

Pierre-Yves Courand, Helena Pereira, Costantino Del Giudice, Philippe Gosse, Matthieu Monge, Guillaume Bobrie, Pascal Delsart, Claire Mounier-Vehier, Pierre Lantelme, Thierry Denolle and 17 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01570777 (Renal Denervation in Patients With Resistant Hypertension), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01570777 phase4completednot on this map

Renal Denervation in Patients With Resistant Hypertension

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2012 to 2018Enrolled121ConditionsHypertension, Resistant to Conventional Therapy, Renal DenervationArmsrenal denervation and optimized medication regimen, optimized medication regimen
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Renal denervation for resistant hypertension.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. 2022 Renal denervation therapy for the treatment of hypertension: a statement from the Thai Hypertension Society.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Article
  9. Assessment of arterial stiffness to predict blood pressure response to renal sympathetic denervation.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022
    Article
  10. Article
  11. 2022 Malaysian Working Group Consensus Statement on Renal Denervation for management of arterial hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022
    Article
  12. Device-based therapies for arterial hypertension.Nature reviews. Cardiology · 2020
    Review
  13. Article
  14. Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficult-to-Treat Hypertensive Patient.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Renal denervation: dark past, bright future?Cardiovascular journal of Africa
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 20 institutions in 1 country.

Pierre-Yves CourandHôpital Croix-Rousse, Cardiology Department, European Society of Hypertension Excellence Centre, Hospices Civils de Lyon, France.
Helena PereiraClinical Research Unit, Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris, France.
Costantino Del GiudiceVascular and Oncological Interventional Radiology Department, Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris, France.
Philippe GosseCardiology/Hypertension Department, Centre Hospitalier Universitaire de Bordeaux Hôpital Saint André, Bordeaux, France.
Matthieu MongeInstitut Mutualiste Montsouris, Paris, France.
Guillaume BobrieHypertension Unit, Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris, France.
Pascal DelsartHôpital Cardiologique, Médecine Vasculaire et HTA, Centre Hospitalier Régional Universitaire de Lille, France.
Claire Mounier-VehierHôpital Cardiologique, Médecine Vasculaire et HTA, Centre Hospitalier Régional Universitaire de Lille, France.
Pierre LantelmeHôpital Croix-Rousse, Cardiology Department, European Society of Hypertension Excellence Centre, Hospices Civils de Lyon, France.
Thierry DenolleHôpital Arthur Gardiner, Centre d'excellence en HTA Rennes-Dinard, Dinard, France.
Caroline DourmapHôpital Arthur Gardiner, Centre d'excellence en HTA Rennes-Dinard, Dinard, France.
Jean Michel HalimiHôpital Bretonneau, Tours, France.
Xavier GirerdHôpital de la Pitié Salpétrière, Paris, France.
Patrick RossignolInserm Centre d'Investigations Cliniques-1433 Inserm U1116 CHRU Nancy F-CRIN INI-CRCT Université de Lorraine, Nancy, France.
Faiez ZannadInserm Centre d'Investigations Cliniques-1433 Inserm U1116 CHRU Nancy F-CRIN INI-CRCT Université de Lorraine, Nancy, France.
Olivier OrmezzanoCHU de Grenoble, France.
Bernard VaisseCHU de la Timone, Marseille, France.
Daniel HerpinCardiology Department, CHU de Poitiers, Poitiers, France.
Jean RibsteinHôpital Lapeyronie, Montpellier, France.
Beatrice BouhanickCHU Rangueil, Toulouse, France.
Jean-Jacques MouradHôpital Avicenne, Bobigny, France.
Emile FerrariHôpital Pasteur, Nice, France.
Gilles ChatellierClinical Research Unit, Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris, France.
Marc SapovalVascular and Oncological Interventional Radiology Department, Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris, France.
Arshid AzarineVascular and Oncological Interventional Radiology Department, Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris, France.
Michel AziziINSERM CIC1418 Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris, France michel.azizi@aphp.fr.
DENERHTN Investigators
Délégation Paris 5 · FRAssistance Publique – Hôpitaux de Paris · FRInserm · FRHôpital Pasteur · FRCentre Hospitalier Universitaire de Lille · FRUniversité Claude Bernard Lyon 1 · FRCentre Hospitalier Universitaire de Toulouse · FRCentre Hospitalier Universitaire de Tours · FRHôpital Nord · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Poitiers · FRCentre Hospitalier Universitaire de Rennes · FRHôpital de la Timone · FRInstitute Mutualiste Montsouris · FRSorbonne Université · FRHôpital Avicenne · FRHôpital Lapeyronie · FRHôpital Rangueil · FRUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe DENERHTN (Renal Denervation for Hypertension) trial confirmed the efficacy of renal denervation (RDN) in lowering daytime ambulatory systolic blood pressure when added to standardized stepped-care antihypertensive treatment (SSAHT) for resistant hypertension at 6 months. METHODS AND

resultsThis post hoc exploratory analysis assessed the impact of abdominal aortic calcifications (AAC) on the hemodynamic and renal response to RDN at 6 months. In total, 106 patients with resistant hypertension were randomly assigned to RDN plus SSAHT or to the same SSAHT alone (control group). Total AAC volume was measured, with semiautomatic software and blind to randomization, from the aortic hiatus to the iliac bifurcation using the prerandomization noncontrast abdominal computed tomography scans of 90 patients. Measurements were expressed as tertiles. The baseline-adjusted difference in the change in daytime ambulatory systolic blood pressure from baseline to 6 months between the RDN and control groups was -10.1 mm Hg (

conclusionsRDN plus SSAHT resulted in a larger decrease in daytime ambulatory systolic blood pressure than SSAHT alone in patients with a lower AAC burden than in those with a higher AAC burden. This larger decrease in daytime ambulatory systolic blood pressure was not associated with a decrease in estimated glomerular filtration rate. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01570777.

Indexed as

Arterial PressureAdultAgedAntihypertensive AgentsAorta, AbdominalAortic DiseasesAortographyComputed Tomography AngiographyFemaleFranceGlomerular Filtration RateHumansHypertensionKidneyMaleMiddle AgedAntihypertensive Agentsantihypertensive therapy/sympathetic nervous systemaortic calcificationaortic diseaseatherosclerosisrenal denervationresistant hypertension

Identifiers

PMID29018027
PMCPMC5721886
OpenAlexW2761065353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.